Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. R...

Full description

Bibliographic Details
Main Authors: Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral Grandhi, Shridar Ganesan, Deborah L. Toppmeyer, Lindsay Potdevin, Kathleen Toomey, Kim M. Hirshfield, Nancy Chan
Format: Article
Language:English
Published: Karger Publishers 2021-06-01
Series:Case Reports in Oncology
Subjects:
metaplastic breast cancer
exceptional response
immunotherapy
program death ligand-1
Online Access:https://www.karger.com/Article/FullText/515510

Similar Items

Similar Items